Operating Income
Labcorp Holdings Operating Income increased by 42.3% to $380.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.8%, from $326.00M to $380.80M. Over 3 years (FY 2021 to FY 2025), Operating Income shows a downward trend with a -23.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher operating income indicates strong operational efficiency and pricing power, while a decline suggests rising costs or weakening demand.
Detailed definition
Operating income is the profit realized from a company's core business operations after deducting all operating expenses...
Peer comparison
A standard benchmark for operational performance; peers are compared based on operating margin percentages.
operating_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $704.10M | $766.90M | $519.70M | $687.90M | $428.80M | $374.00M | $28.50M | $329.80M | $266.30M | $252.30M | $321.30M | $294.80M | $254.10M | $216.50M | $326.00M | $394.50M | $396.60M | $267.60M | $380.80M |
| QoQ Change | — | +8.9% | -32.2% | +32.4% | -37.7% | -12.8% | -92.4% | >999% | -19.3% | -5.3% | +27.3% | -8.2% | -13.8% | -14.8% | +50.6% | +21.0% | +0.5% | -32.5% | +42.3% |
| YoY Change | — | — | — | — | -39.1% | -51.2% | -94.5% | -52.1% | -37.9% | -32.5% | -2.6% | +10.7% | +0.7% | — | +1.5% | +33.8% | +56.1% | +23.6% | +16.8% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $441.50M | $387.40M | $359.50M | $427.50M | $482.80M | $450.40M | $419.20M | $458.70M |
| Biopharma Laboratory Services | — | — | — | $106.90M | $123.30M | $132.20M | $136.10M | $120.70M |
| Corporate Segment | -$180.30M | -$172.50M | -$189.10M | -$132.40M | -$139.20M | -$109.90M | -$100.70M | -$116.60M |
| Covance Drug Development | $107.40M | $120.90M | — | — | — | — | — | — |
| Drug Development | $107.40M | $120.90M | — | — | — | — | — | — |
| Total | $294.80M | $254.10M | $216.50M | $326.00M | $394.50M | $396.60M | $267.60M | $380.80M |
Covance Drug Development, Drug Development were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Operating Income at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's operating income?
- Labcorp Holdings (LH) reported operating income of $380.80M in Q1 2026.
- How has Labcorp Holdings's operating income changed year-over-year?
- Labcorp Holdings's operating income increased by 16.8% year-over-year, from $326.00M to $380.80M.
- What is the long-term trend for Labcorp Holdings's operating income?
- Over 3 years (2021 to 2025), Labcorp Holdings's operating income has grown at a -23.1% compound annual growth rate (CAGR), from $3.05B to $1.38B.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.